Anti Cancer drug: Making it Patient-driven, not Disease-driven
Introduction: French compatriots Ipsen and bioMérieux, have been few most potential companies since 2007 in the development of companion assay to assess patient benefit from a compound useful for treating several severe forms of cancers. The partnership between two companies…